Exact Sciences Q4 2024 Earnings Report
Key Takeaways
Exact Sciences achieved 10% YoY revenue growth in Q4 2024, reaching $713.42M. Screening revenue grew by 14%, while Precision Oncology revenue remained flat. However, an $838M impairment charge led to a substantial net loss of $864.59M, significantly higher than the prior year's loss of $49.77M. Adjusted EBITDA improved to $75.38M with an 11% margin.
Total revenue grew 10% YoY to $713.42M.
Screening revenue increased by 14%, driven by Cologuard.
Net loss widened to $864.59M due to an $838M impairment charge.
Adjusted EBITDA rose to $75.38M with an 11% margin.
Exact Sciences Revenue
Exact Sciences EPS
Exact Sciences Revenue by Segment
Forward Guidance
Exact Sciences expects revenue growth between 9%-12% in 2025, driven by new product launches and expanded screening adoption. Adjusted EBITDA is projected to improve, indicating better profitability.
Positive Outlook
- Full-year 2025 revenue guidance of $3.03B - $3.09B (+9% - 12% YoY).
- Screening revenue expected to grow to $2.35B - $2.39B.
- Precision Oncology revenue forecasted at $675M - $695M.
- Adjusted EBITDA projected to rise to $410M - $440M.
- Launch of Cologuard Plus, Oncodetect, and Cancerguard expected in 2025.
Challenges Ahead
- Large impairment charges could impact profitability in the near term.
- Precision Oncology revenue showed minimal growth in Q4 2024.
- Continued net losses despite revenue growth.
- High operating expenses, including R&D and marketing investments.
- Potential reimbursement and regulatory challenges for new test launches.
Revenue & Expenses
Visualization of income flow from segment revenue to net income